Last updated: February 13, 2026
Overview of NDC 51407-0071
NDC 51407-0071 refers to Jakafi (ruxolitinib), a Janus kinase (JAK) inhibitor approved for treating myelofibrosis, polycythemia vera, and cutaneous T-cell lymphoma. It is developed by Incyte Corporation. Since its approval in November 2011, Jakafi has established a strong market position with ongoing growth driven by expanding indications.
Market Landscape
Market Size and Growth Drivers
- Global Market Value: Estimated at approximately $2.8 billion in 2022.
- Compound Annual Growth Rate (CAGR): Projected at 13.2% from 2023 to 2028, according to IQVIA.
- Indications: Growing use in myeloproliferative disorders; newer indications under development expand the potential patient pool.
- Competitive Landscape: Competes primarily with fedratinib (Inrebic) and upcoming therapies targeting similar hematologic conditions.
Key Market Factors
- FDA Approvals: The drug received FDA approval for myelofibrosis (2011), polycythemia vera (2019), with ongoing trials for other indications.
- Market Penetration: High adoption in hematologists' practices; off-label use in other inflammatory conditions.
- Pricing Strategies: Premium pricing in line with comparable biologic therapies; significant rebates and discounts influence net pricing.
Pricing and Cost Analysis
Current List Prices
- Standard Dosage: 5 mg, 10 mg, 15 mg, and 20 mg tablets.
- Wholesale Acquisition Cost (WAC): Estimated at approximately $1,950 per 60-count bottle of 15 mg tablets (as of early 2023).
- Per-Unit Price: Roughly $32.50 per tablet (~15 mg).
Reimbursement and Net Prices
- Average Selling Price (ASP): Roughly 15-20% below WAC due to discounts.
- Insurance Reimbursements: Typically cover 80-90% of drug costs in commercial markets; patient out-of-pocket costs vary based on copay assistance programs.
Price Trends
- Historical Adjustment: Prices have increased approximately 2-3% annually since market launch, with a slight acceleration following expanded indications.
- Market Pressures: Price pressures from biosimilars or alternative JAK inhibitors may moderate future increases.
Future Price Projections
Short-Term (Next 2 Years)
- Stable Pricing: Expect WAC to remain in the $1,950 range for a 60-count bottle; minor increases (~1-2%) likely aligned with inflation and manufacturing costs.
- Potential Discounts: Volume-based rebates and formulary negotiations may reduce net prices by 10-15%.
Medium to Long-Term (3-5 Years)
- Expanded Indications: Launch of new indications (e.g., other hematologic malignancies) could justify price increases of 3-5% annually.
- Market Competition: Entry of biosimilars or new therapeutics may compress margins; pricing may need to be competitive.
- Regulatory and Policy Changes: Price controls or value-based pricing models could influence listed prices.
Factors Influencing Price Trends
- Patent Expiry: Current patents extend into the late 2020s, delaying biosimilar competition.
- Market Penetration: Higher adoption rates usually support price stability; slow uptake could lead to downward pressure.
- Pharmaceutical Policies: US CMS and private payers’ policies on drug pricing and rebates.
Strategic Insights
- Market Penetration: Focus on expanding indications and geographic markets to sustain revenue.
- Pricing Strategy: Maintain a premium price point with value propositions supported by clinical efficacy.
- Cost Management: Optimize manufacturing and distribution to control costs amid pricing pressures.
Key Takeaways
- NDC 51407-0071 (Jakafi) dominates the hematology space with a current WAC around $1,950 per 60-tablet bottle.
- The global market is growing at 13.2% CAGR, driven by expanded indications and higher adoption.
- Price projections indicate stability in the short term, with moderate increases aligned to indication breadth.
- Market competition and policy shifts are likely to influence longer-term pricing strategies.
- Reimbursement variability and rebates significantly impact net prices.
FAQs
1. What is the main therapeutic use of NDC 51407-0071?
Jakafi (ruxolitinib) is primarily used for treating myelofibrosis, polycythemia vera, and cutaneous T-cell lymphoma.
2. How does the current pricing compare to similar drugs in hematology?
It maintains a premium compared to older therapies but aligns with newer biologics in that space, with WAC around $32.50 per tablet.
3. Are biosimilars expected to impact Jakafi’s price?
Biosimilar competition is unlikely until patent expiry in the late 2020s, which may eventually lower prices.
4. What are the key factors influencing future price increases?
Indication expansion, market penetration, regulatory changes, and competitive landscape shape future pricing.
5. How do rebates and discounts affect the net revenue for this drug?
Rebates and discounts can reduce net prices by 10-15%, affecting overall revenue potential despite high list prices.
Sources:
[1] IQVIA, Market Research Reports, 2022.
[2] Incyte Corporation SEC Filings, 2023.
[3] FDA Drug Approvals and Labeling, 2021-2022.
